Q1 2026 earnings call: neffy revenue growth, CVS Caremark prior-auth update, $199 cash option, guidance & risks.

Thank you, Justin, and good morning, everybody, and thank you for joining us on the call. During the quarter, we continued to focus on key drivers of growth, which are expanding access, making neffy ...

ARS Pharma commercializes Neffy, an epinephrine nasal spray intended for emergency treatment of Type I allergic reactions.

Forbes contributors publish independent expert analyses and insights. Jesse Pines is an expert in healthcare innovation and wellness. This voice experience is generated by AI. Learn more. This voice ...

Net Product Revenue: $72.2 million for the first full year of commercial sales. Total Revenue: $84.3 million, including collaboration and supply revenue. R&D Expenses: $13.2 million, primarily for ...

The proposed rule aims to improve prior authorization for prescription drugs by establishing and requiring electronic prior ...

The effort, part of the agency’s ambitious Health Tech Ecosystem, aims to accelerate the industry’s progress before ...